Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Carboplatin With or Without Topotecan in Ovarian Cancer
NCT00006454Phase 3Completed
- Sponsor
- AGO Study Group
- Start
- Dec 1999
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of topotecan in ovarian cancer and fallopian tube cancer (PFTC) (2 arms), sponsored by AGO Study Group. Primary endpoints: Overall Survival up to 5 years and Progression-Free Survival up to 5 years. Started Dec 1999; status: completed.
02
Drugs
topotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00006454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006454.